Background. In the era of destination continuous flow left ventricular assist devices (LVAD), the decision of whether a patient will tolerate isolated LVAD support or will need biventricular support (BIVAD) can be challenging. Incorrect decision making with delayed right ventricular (RV) assist device implantation results in increased morbidity and mortality. Continuous flow LVADs have been shown to decrease pulmonary hypertension and improve RV function. We undertook this study to determine predictors in the continuous flow LVAD era that identify patients who are candidates for isolated LVAD therapy as opposed to biventricular support.
Methods. We reviewed demographic, hemodynamic, laboratory, and echocardiographic variables for 218 patients who underwent VAD implant from 2003 through 2011 (LVAD [ 167, BIVAD [ 51), during the era of continuous flow LVADs.
Results. Fifty preoperative risk factors were compared between patients who were successfully managed with an LVAD and those who required a BIVAD. Seventeen variables demonstrated statistical significance by univariate analysis. Multivariable logistic regression analysis identified central venous pressure >15 mmHg (OR 2.0, "C"), severe RV dysfunction (OR 3.7, "R"), preoperative intubation (OR 4.3, "I"), severe tricuspid regurgitation (OR 4.1, "T"), heart rate >100 (OR 2.0, Tachycardia -"T") -CRITT as the major criteria predictive of the need for biventricular support. Utilizing these data, a highly sensitive and easy to use risk score for determining RV failure was generated that outperformed other established risk stratification tools.
Conclusions. We present a preoperative risk calculator to determine suitability of a patient for isolated LVAD support in the current continuous flow ventricular assist device era. [1] [2] [3] . Outcomes are striking when compared to those of optimal medical management, and are quickly approaching those of the reference standard, cardiac transplantation. In particular, VADs have demonstrated major improvements in quality of life as well as survival [1] [2] [3] [4] [5] [6] . A majority of the devices implanted currently are continuous flow devices, including the Food and Drug Administration-approved HeartMate II (Thoratec, Pleasanton, CA) pump, given proven device durability and reliability [7] . Unfortunately, irreversible right ventricular (RV) failure remains a major contraindication for isolated left ventricular assist device (LVAD) implant. Currently, continuous flow devices are only available for left ventricular support, with anecdotal reports of utilization in the right ventricle. Therefore, patients with severe biventricular failure are effectively not candidates for destination VAD therapy.
Biventricular assist device (BIVAD) implantation is a reasonable strategy for patients being bridged to recovery or transplant but this is not a viable option forpatients who will be reliant on a VAD for destination therapy. Numerous reports have demonstrated increased mortality with delayed institution of biventricular support rather than early implant of a BIVAD [8] [9] [10] . Therefore, it is critical to identify the patients who will successfully tolerate isolated LVAD implant without RV failure at the outset of surgical decision making. Both our group and others have devised risks scores to determine whether a patient will tolerate isolated LVAD support or whether that patient will need biventricular support [11] [12] [13] [14] . However, these risk stratification tools were devised from study populations in which pulsatile flow devices were the principal implants, before the advent of newer continuous flow devices.
It has been suggested that continuous flow devices may have a beneficial effect on improving pulmonary hypertension and unloading the right ventricle, thereby improving RV function [15] [16] [17] [18] [19] . Thus, it is possible that patients who traditionally were not candidates for LVAD implant may now be able to tolerate univentricular support. Additionally, with experience cardiac surgeons have learned operative and pharmacologic strategies to better improve or preserve RV function during the perioperative period. Therefore, given the availability of newer, continuous flow devices and our enhanced understanding of mechanical circulatory support physiology, patients who may not have initially tolerated an isolated LVAD now may be candidates in the modern era. Kormos and colleagues [20] have very nicely demonstrated a very low incidence of RV failure after implant of the HeartMate II LVAD, based upon the HeartMate II bridge to transplant clinical trial [20] . But they also noted significantly worse outcomes with RV failure after continuous flow LVAD implant, stressing the importance of accurately predicting the need for biventricular support. We undertook this study to develop a simple and easily memorized risk stratification tool to determine whether a patient will tolerate an isolated LVAD, as opposed to 
Patients and Methods

Study Design
All patients who underwent either isolated LVAD (n ¼ 167) or BIVAD (n ¼ 51) implant from 2003 through 2011 at the Hospital of the University of Pennsylvania were retrospectively reviewed. The device profiles for these patients are presented in Tables 1 and 2 . As many patients presented in acute cardiogenic shock, several patients were supported with short-term univentricular or biventricular mechanical devices. Patients in the BIVAD cohort included those who underwent planned BIVAD implantation and those who had right heart failure after initial isolated LVAD implantation requiring delayed insertion of a temporary or long-term RV assist device (n ¼ 7). The decision to implant a BIVAD was made collectively by the heart failure team, which included a cardiac surgeon and heart failure cardiologist. This decision was based upon clinical presentation, hemodynamics as determined by a pulmonary artery catheter, and echocardiographic assessment of the right ventricle. Right ventricular function was measured echocardiographically by evaluation of regional myocardial contractility, tricuspid valvular competence, and tricuspid annular motion. We defined severe RV dysfunction based upon echocardiographic parameters, taking into account RV contractility, tricuspid regurgitation, and tricuspid annular motion. The RV function was initially determined by a cardiac anesthesiologist board certified in echocardiography and confirmed by an independent cardiologist evaluating the same study in a separate setting.
Data Acquisition
All patient data were collected preoperatively and retrospectively analyzed. Hemodynamic variables were acquired immediately preoperatively from radial artery and pulmonary artery catheters. Echocardiographic data were obtained from preoperative transesophageal echocardiography studies. Preoperative circulatory support was defined as a need for an intraaortic balloon pump, temporary VAD, or extracorporeal membrane oxygenation preoperatively. Cardiac output and mixed venous oxygen saturation were obtained using a continuous cardiac output pulmonary artery catheter and confirmed using measured oxygen tension and manual calculation of cardiac output. Right ventricular stroke work index (RVSWI) was calculated as SVI Â (MPAP À CVP) Â 0.136, where SVI is stroke volume index, MPAP is mean pulmonary artery pressure, and CVP is central venous pressure. A total of 50 different variables were compared between the LVAD and BIVAD cohorts. In all, 196 of 218 patients had sufficient information to be included in the analysis; and 45 of 51 BIVAD patients had sufficient information to be included in the analysis.
The study was approved by the Institutional Review Board of the University of Pennsylvania. After initial data accrual, all patient identifiers were removed from the database, before statistical analysis. All tests were two-tailed, and p less than 0.05 was considered statistically significant. Multivariable logistic regression was used to model a binary outcome of LVAD or BIVAD support (planned or delayed) for each patient in the study population. Of 50 fixed-effect variables, 20 were identified in univariate analysis (threshold p < 0.15) for inclusion into a stepwise logistic regression model (entry limit p < 0.1). All continuous variables were converted into categorical variables before inclusion in the multivariable analysis.
Conversion was performed with serial c 2 testing with stepwise threshold progression to determine maximal divergence between LVAD and BIVAD groups. To facilitate clinical utilization at the bedside, a simple risk score was generated where each of the five variables identified in the multivariable logistic regression model is assigned a score of 0 or 1 (Thus overall CRITT minimum score 0, maximum score 5). Model fit and predictive power were assessed using Hosmer-Lemeshow goodness-of-fit testing and receiver-operating characteristic curves. A separate subgroup analysis was performed to determine the predictive power of the scoring system for isolated continuous flow LVAD patients. The statistical analysis was performed using IBM SPSS Statistics for Macintosh, version 19.0 (SPSS, Armonk, NY).
Results
Univariate Analysis
Analysis of individual variables revealed several key criteria that were distinctly different between LVAD and BIVAD cohorts (Tables 3-6 ). Patients in the BIVAD cohort were more likely to be female and have pulmonary hypertension. Systemic hypertension, hypercholesterolemia, stroke, and chronic kidney disease were significantly more frequent in the LVAD cohort (Table 3) . Patients who underwent BIVAD implant were more likely to require mechanical ventilation, have severe preoperative RV dysfunction, or require an intraaortic balloon pump or other circulatory support when compared with patients who tolerated isolated LVAD therapy (Table 3) . Severe tricuspid regurgitation was also more common in the BIVAD cohort preoperatively (Table 4) . Univariate analysis of preoperative hemodynamic variables revealed an elevated heart rate, elevated central venous pressure, and diminished RV stroke work index as variables indicative of the need for biventricular support (Table 5) . With regard to laboratory values, an elevated white blood cell count, international normalized ratio, alanine aminotransferase, and aspartate aminotransferase were significantly more likely among patients in the BIVAD cohort when compared with the LVAD group (Table 6 ).
Multivariate Logistic Regression Analysis
A stepwise multivariable logistic regression model was created by incorporating significant variables identified by univariate analysis. Variables predictive of the need for biventricular support included severe RV dysfunction, severe tricuspid regurgitation, preoperative mechanical ventilation, an elevated central venous pressure (>15 mm Hg), and a heart rate more than 100 beats per minute (Table 7) .
Quantitative Preoperative Risk Score-CRITT Score
For simplicity and efficiency of use, a 5-point risk score was developed based on the clinical variables identified in the multivariable logistic regression model. Instead of weighting variables with coefficients based on their respective odds ratios, each variable is given a binary response. Therefore, if a patient satisfies the at-risk criterion (eg, preoperative central venous pressure >15 mm Hg), they are assigned a score of 1 for that variable. Alternatively, if a patient does not satisfy the at-risk criterion for a specific variable, they are assigned a score of 0 for that variable. Thus, 0 or 1 point is allotted for each of the five variables in the "CRITT" score: CVP greater than 15 mm Hg (C); severe RV dysfunction (R); preoperative mechanical ventilation/intubation (I); severe tricuspid regurgitation (T); and tachycardia (T). The model fit and predictive power of the 5-point risk score were excellent when applied to the University of Pennsylvania VAD experience (c statistic 0.8). A score of 2 or more points provided a sensitivity of 84%, specificity of 63%, and negative predictive value of 93%. Thus, 93% of patients with a score of 1 or less underwent successful isolated LVAD therapy (95 of 102 patients who could be scored). Additionally, 80% of patients with a score of 4 or higher required biventricular assistance (8 of 10 patients). Based on this model we recommend an isolated LVAD for a score of 0 or 1 and a BIVAD for a score of 4 or 5. Patients with a score of 2 or 3 are in the gray area and may be able to tolerate an isolated LVAD with appropriate pharmacologic or temporary RVAD support. The distribution of scores for the LVAD and BIVAD cohorts in this study has been summarized in Figure 1 .
The area under the curve for the CRITT score was 0.80 AE 0.04 (Fig 2) . Receiver-operating characteristic curves were also generated for previously reported predictors of RV failure, including central venous pressure, mean pulmonary arterial pressure, total bilirubin, creatinine, and aminotransferase levels (Fig 2, Table 8 ). Comparison of the area under the curve of the CRITT score with that of other previously reported predictors demonstrated the CRITT score to be most predictive of RV failure requiring mechanical support (p < 0.05 for all comparisons). When applied to the CF LVAD only subset, the predictive power was improved (c statistic 0.85 AE 0.04). The CRITT score demonstrated a sensitivity of 87%, specificity of 75%, and negative predictive value of 93% for continuous flow LVADs.
Comment
We have developed a reliable risk stratification tool that can be applied to patients in acute or chronic heart failure to determine suitability for univentricular support, or alternatively, need for biventricular support. Whereas many prior published risk models for right heart failure are cumbersome and often involve complex calculations, the CRITT score is very easy to use and remember. The CRITT score can be quickly calculated at the bedside without a complex calculation, and a score less than 2 is highly predictive of the ability to tolerate isolated LVAD therapy (negative predictive value of 93%). This score is PREDICTING RIGHT HEART FAILURE AFTER LVAD not only applicable to patients with long-standing heart failure who are about to undergo placement of a continuous flow LVAD for destination therapy, but also to previously healthy patients who present in acute cardiogenic shock. The development of RV failure after LVAD implantation is multifactorial, and includes factors such as increased preload, ventricular ischemia, and ventricular geometric mechanical interdependence. Numerous studies have closely examined both measures reflective of the consequences of RV dysfunction, as well as those that are directly diagnostic of reduced RV contractility [9, 11, 12, [21] [22] [23] [24] [25] [26] [27] [28] . These studies have identified many logical preoperative hemodynamic and laboratory measures as predictors of RV failure, including a decreased pulmonary artery pressure [9, [21] [22] [23] or RVSWI [9, 11, 22, 23] , and elevated central venous pressure [24, 28] , hepatic transaminases [12, 21, 23] , bilirubin [12, [25] [26] [27] , or creatinine [11, 12, 21] . Clearly, hemodynamic variables directly reflect increases in preload and afterload, and reductions in RV contractility, whereas consequences of RV failure such as venous congestion and organ hypoperfusion are reflected in hepatic and renal abnormalities.
Unfortunately, the variables (or combinations thereof) identified as significant risk factors for RV failure are not consistent across the number of studies in the literature. For example, preoperative elevations in central venous pressure was associated with a higher risk of RV failure in our study as well as others [24, 28] , but was not confirmed in others [12, 23, [25] [26] [27] . In a study examining predictors of RV failure that occurred in 11 of 100 HeartMate IP and VE patients, Fukamachi and colleagues [23] showed that a lower mean pulmonary artery pressure and RVSWI, and elevated aminotransferase levels conferred an increased risk of RV failure. In the present study, although such laboratory parameters were significant on univariate analysis (eg, aminotransferases and creatinine), the final multivariable model consisted mainly of direct hemodynamic and echocardiographic measurements of RV performance. When the CRITT score was compared with previously published risk factors for RV failure, the CRITT score emerged as a superior risk stratification tool in our study population that included newer devices and postoperative management techniques.
Differences in risk stratification tools between studies can be attributed to selection bias, time period over which the study was conducted, and indications for VAD therapy. Limitations of prior studies include a low incidence of RV failure [9, 22, 23] , vague definitions of RV failure [26] , as well as a lack of multivariable analysis [21, 23, [25] [26] [27] . Although studies vary in the preoperative variables each identifies as predictors of RV failure, the overall group and type of variables remain the same.
It is important to note that as practice patterns and patient selection vary across institutions, and as VAD technology evolves, each physician should adopt a particular way of stratifying risk for RV failure. However, such risk stratification tools should probably include variables that are directly diagnostic of RV performance and reflective of consequences of RV dysfunction. As we move forward into newer and more advanced continuous flow VADs, new risk scores should ultimately be created and validated against national data. Until that time, we present a simple, easy to remember risk stratification tool that can guide clinicians and heart failure teams in the surgical management of end-stage heart failure in an era of continuous flow LVADs.
DISCUSSION
DR ASHISH SHAH (Baltimore, MD): I have a couple of comments. I think you have pointed out the flaw of your study, and that is that you are basing this on a cohort of patients that if you look at your device selection, it means that you are doing a good job of picking the devices; the patients are really, really sick.
I think the question we all have is about the patient who you are presenting for a destination therapy ventricular assist device (VAD), a univentricular support that looks pretty good at the bedside and who is the guy that you commit to a HeartMate II, and now you are stuck with a right ventricle (RV) that doesn't work, and that's a big problem, because then, for the most part, you are using some short-term support for a little while and then how do you get that guy through, or should we be bridging these people with short-term devices and then allowing them to be prepared for univentricular support. I think those are the complex questions that we would like to answer.
And so it's hard from that cohort, in my mind, where you have got all these almost short-term devices on one side, really, and then these long univentricular destination therapy patients coming from home on the other side in a small group, to see how you can really use one scoring system across all of these.
DR GOLDSTONE: Actually, I think the slide is somewhat misleading. The devices shown in the biventricular assist device (BIVAD) group are only the devices used for the right ventricular support. They are not the primary left ventricular assist device (LVAD) that was implanted.
DR SHAH: So all the patients that were included in the cohort are folks whose upfront goal was univentricular support? DR GOLDSTONE: No, the cohort also includes intended biventricular assist implants.
DR SHAH: There is propensity in there that's biased by your implant surgeons and the team?
DR GOLDSTONE: To a certain extent. We decide preoperatively as a team (surgeon and heart failure cardiologist) who will be an acceptable candidate for univentricular vs biventricular support. And we have gotten better, as the incidence of biventricular support or patients requiring delayed biventricular support was approximately 40%. In the present cohort, now in the era of continuous flow LVADs, it is 23%.
In terms of the intermediate risk patients that you are referring to, I have a few comments. One, I agree with you. I think perhaps some should be considered for temporary right ventricular support, or now that perioperative management has improved, you may be able to get by with pharmacologic management. However, they may need an RVAD, and one may need to consider putting in a temporary RVAD as a bridge to right ventricular recovery that can ultimately be explanted.
All of that would hopefully become somewhat moot once longterm devices for biventricular support are available for destination therapy.
DR JAY K. BHAMA (Pittsburgh, PA): A quick question. First of all, that was a great talk, I enjoyed it, and you did a great job presenting it. Two of the characteristics that you looked at were echo-based characteristics, RV dysfunction and tricuspid regurgitation. What are you basing those on? Are those based on the first echocardiogram they get to evaluate their heart failure status or is it before they go to the operating room (OR), in the OR? When are you reading it? DR GOLDSTONE: Those are preoperative echoes before they go to the OR.
DR BHAMA: And who reads them? We get varying reports on echos. We can have one echocardiographer read it and give you one report and another one give you completely different views. So is this something that the surgeon is looking at or is it something that the cardiologist is reading?
DR GOLDSTONE: For this study, it was based on the echo reports. It was what the cardiologist reported. Moving forward, it might be better to have clearly defined variables such as using tricuspid annular plane systolic excursion (TAPSE), a more quantitative as opposed to semiquantitative analysis of RV function.
DR BHAMA: One thing that we are doing at UPMC using speckle tracking on the echo, and we are trying to correlate it with our own results, retrospectively. One of our cardiologists, Mark Simon, has been doing this, and he will create a report for us on a prospective patient based upon that patient's echo speckle-tracking data and what the predicted chance of needing RV support will be. That's another thing you might want to consider looking at.
DR GOLDSTONE: I'm not familiar with speckle tracking.
DR BHAMA: It's a type of software platform where they put marks on the RV that track its motion. They get a good picture of the RV and then they study how those tracks move in time.
DR SHAH: I think that's a problem there, right? The RV is really difficult to image with the chest wall, and that's why this is really challenging.
DR SHAHAB A. AKHTER (Chicago, IL): Nice presentation. Your presentation brings up the point that Dr Shah mentioned in terms of center-specific and patient-specific sorts of characteristics. We studied 185 continuous flow LVADs implanted at our center over the past 4 years, and we had a 5% incidence of RV failure requiring a temporary RVAD and an additional 5% to 6% that needed prolonged inotropic support. Maybe it's a patient population issue.
The other thing is, anecdotally, we just use a very simple strategy of mean PA pressure to CVP ratio, and if that is 2:1 or greater, we feel pretty confident that we are either going to come out fine with just an LVAD or use a temporary RVAD for 3 to 5 days. One other thing, these RV risk scores are all great I think, primarily from an academic perspective, but even the Michigan group and other groups, when you ask them, do you really calculate these scores and discuss them with patients, et cetera, preoperatively, does it really help in driving your clinical decision about using an isolated LVAD versus going up to a TAH or a Thoratec, the answer is always "no." So in your institution, is this really being utilized to drive clinical decision-making? DR GOLDSTONE: We do not always formally calculate the exact value from the previous risk score, but we do consider each of the variables.
DR AKHTER: For example, in your program, it's a busy program, what is the incidence of patients going in for biventricular support rather than just having a CentriMag available? DR GOLDSTONE: I currently do not know that data offhand.
DR SHAH:
Where do you hold off on offering a device to the patient? You say, well, your RV risk score is too high. Why don't we try some time and diuresis and see if we can get the numbers better.
DR CHARLES HOOPES (Lexington, KY): Your point is well taken. With us, patient selection, timely intervention, and perioperative management with the device is the biggest predictor of RV failure, because we have taken your type of scores for acute cardiogenic shock, put them on central extracorporeal membrane oxygenation, and made all those numbers perfect; they're perfect. Half those patients still require an RVAD, half of those patients don't. So, clearly, just making those numbers better doesn't fix everything.
We don't have good RV biomarkers, and that's what we really want. If there was an RV-specific biomarker that this is where you are on the curve of RV failure, that would be great, but the best we have are things like B-type natriuretic peptides-they are reasonable, but that's, again, for biventricular failure. It would be nice if we had a true RV-specific biomarker.
It's a very different system, and yet the way we manage them in mechanical circulatory support is, we caught an RVAD, we caught an LVAD. It's the same device for two sides of the heart with fundamentally different physiological parameters.
DR JOSHUA ROBERT SONETT (New York, NY): It's also the same problem we have for pulmonary hypertension in transplant. They have crappy lung allocation scores because we're not good at telling who is going to fail or not. It's not the score's problem; it's our problem. We haven't been able to tell people how to give us good scores. And if we get some type of marker, it would be great.
DR BHAMA: It adds to the complexity you mentioned. The RV function also changes after LVAD implant. You are not dealing with the same ventricle before as you are after. So I think it just adds another level of complexity.
DR HOOPES: I created RV failure when I started, I can assure you. I got so upset I said, let's crank that thing all the way up, and all of a sudden you have anesthesia say, wow, you really got that LV decompressed, and then 20 seconds later your pressure is 40/ 40 because the septum gets volume loaded. We don't see it as much in the axial flows as we did with the HeartMate I.
I'm the biggest predictor of RV failure. We live and die by the echocardiogram, and without the echo I would pretty much keep the septum midline. And even the resident has gotten big enough now to know if that happens, he'll turn off the VAD, a whopping dose of epinephrine, and usually we can sneak back out again, because I honestly don't believe that there's such a thing as short-term-I just don't believe the RV recovers any more than the LV recovers. I just don't buy it.
I've made mistakes where I've supported my iatrogenic injury for 5 days and fixed my mistake, but I don't really think I've ever taken an RV that was sick and I made it better and it recovered. I just don't believe right ventricles recover any faster than left ventricles recover. I just don't think it's true. I've seen no data to support it. DR AKHTER: I think a lot of that goes to whether you're a nonischemic or an ischemic in terms of etiology. That would also be helpful to stratify your score.
DR SHAH: It's provocative. I think more of this as are we creating Fontan circulation in patients or are we really trying to have some remodeling of pulmonary vascular bed that the RV is going to get better. I thought the one abstract that's out there about doing septostomies, it was experimentally, as a way of supporting the RVs is very intriguing. Instead of closing all these patent foramen ovales like we're supposed to, pop them open like the pediatric guys do.
It's very interesting. I also wonder about these tricuspid interventions. Carmelo Milano would say that ringing these tricuspids seems to decrease the amount of RV dysfunction, or whatever the markers for it, and I don't buy it, either. And we have got some patients who, just like your cohort, a year out, a year later feel okay or they need dobutamine, and I think we still struggle with this.
DR AKHTER:
We focused on does it increase morbidity or mortality, not does it impact long-term RV function.
